kidney cancer
lung cancer
skin cancer

FDA Modifies Dosage Regimen for Nivolumab

On September 13, 2016, the U.S. Food and Drug Administration (FDA) modified the dosage regimen for nivolumab (Opdivo) for the currently approved indications for renal cell carcinoma, metastatic melanoma, and non–small cell lung cancer (NSCLC). The currently approved recommended dosage...

Bladder Cancer
Kidney Cancer
Prostate Cancer

Multitude of Mentors Help Shape an Illustrious Career in Oncology

Sumanta K. Pal, MD, has had a longer career in oncology than many other colleagues his age. Perhaps the reason for that may center on his starting college at the age 13 and medical school at the age of 17. Today this internationally recognized leader in genitourinary cancers is Assistant Professor ...

kidney cancer

Is Obesity a Prognostic Factor for Improved Survival in Metastatic Renal Cell Carcinoma?

In a study investigating the clinical and biologic effects of body mass index on treatment outcomes in patients with metastatic renal cell carcinoma, Albiges et al found that obese patients treated with targeted therapy had improved survival and progression-free survival compared with patients with ...

kidney cancer

Accumulation of Metabolite Fumarate May Be Linked to Hereditary Leiomyomatosis and Renal Cell Cancer

Researchers funded by the Medical Research Council (MRC) have shown that when the metabolite fumarate accumulates in a hereditary form of renal cancer, it leads to an epigenetic reprogramming that drives cancer, according to a study published by Sciacovelli et al in Nature. The tumor growth...

kidney cancer
lung cancer
skin cancer

Incidence of PD-1 Inhibitor–Related Pneumonitis in Advanced NSCLC, Renal Cell Carcinoma, and Melanoma

In a systematic review and meta-analysis reported in JAMA Oncology, Nishino et al identified the rates of PD-1 (programmed cell death protein 1) inhibitor–related pneumonitis in patients with advanced non–small cell lung cancer (NSCLC), renal cell carcinoma, and melanoma. Rates were...

kidney cancer

Extended Active Surveillance Prior to Systemic Therapy May Be Safe in Some Patients With Metastatic Renal Cell Carcinoma

In a phase II trial reported in The Lancet Oncology, Rini et al found that some patients with metastatic renal cell carcinoma can safely undergo active surveillance for an extended duration prior to initiation of systemic therapy. Indolent growth of metastases is known to occur in some patients...

Kidney Cancer

Quality of Life With Nivolumab vs Everolimus in Advanced Renal Cell Carcinoma

Patients with previously treated advanced renal cell carcinoma receiving nivolumab (Opdivo) in the phase III CheckMate 025 trial had improved health-related quality of life compared with those receiving everolimus (Afinitor), as reported by David Cella, PhD, of Northwestern University, Chicago, et...

Kidney Cancer

Final Results of METEOR Trial: Cabozantinib vs Everolimus in Advanced Renal Cell Carcinoma

As reported by Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, et al in The Lancet Oncology, the final results of the phase III METEOR trial indicate significantly improved overall survival with cabozantinib (Cabometyx) vs everolimus (Afinitor) in patients with advanced renal cell carcinoma...

kidney cancer

Metabolic Gene-Expression Profile May Identify Kidney Cancer Patients Unlikely to Benefit From Nivolumab

Renal cell carcinomas (RCC) positive for the protein programmed death ligand 1 (PD-L1) from patients who did not respond to treatment with the anti–PD-1 therapeutic nivolumab (Opdivo) had significantly higher expression of genes associated with metabolism, compared with PD-L1–positive...

kidney cancer

European Study Finds Chromosome 1q Gain Linked to Poorer Outcome in Wilms Tumor Treated With Preoperative Chemotherapy

In a study reported in the Journal of Clinical Oncology, Chagtai et al of the International Society of Paediatric Oncology (SIOP) Renal Tumours Study Group found that chromosome 1q gain was associated with poorer event-free survival in patients with Wilms tumor treated with preoperative...

kidney cancer

Poorer Outcome in Favorable-Histology Wilms Tumor Associated With Chromosome 1q Gain Reported in U.S. Study

The Children’s Oncology Group found that chromosome 1q gain is associated with poorer event-free and overall survival in patients with favorable-histology Wilms tumor. Gratias et al reported these findings in the Journal of Clinical Oncology. Study Details The study involved analysis of...

kidney cancer

When Combined With Targeted Therapy, Cytoreductive Nephrectomy May Improve Survival in Metastatic RCC

In a National Cancer Data Base study reported in the Journal of Clinical Oncology, Hanna et al found that cytoreductive nephrectomy may improve survival in patients receiving targeted therapy for metastatic renal cell carcinoma. Study Details The study involved data from 15,390 patients treated...

kidney cancer

Final Results of METEOR Trial Show Cabozantinib Improves Overall Survival vs Everolimus in Advanced RCC

As reported by Choueiri et al in The Lancet Oncology, the final results of the phase III METEOR trial indicate significantly improved overall survival with cabozantinib (Cabometyx) vs everolimus (Afinitor) in patients with advanced renal cell carcinoma (RCC) that had progressed after previous...

solid tumors
kidney cancer

Improved Quality of Life Reported With Nivolumab vs Everolimus in Advanced Renal Cell Carcinoma

Patients with previously treated advanced renal cell carcinoma receiving nivolumab (Opdivo) in the phase III CheckMate 025 trial had improved health-related quality of life compared with those receiving everolimus (Afinitor), as reported by Cella et al in The Lancet Oncology. Study Details In the ...

kidney cancer

ASCO 2016: Nivolumab Extends Survival for Patients With Advanced Renal Cell Carcinoma Treated Beyond Disease Progression

In a large randomized study, the immunotherapy drug nivolumab (Opdivo), an anti­­–PD-1 (programmed cell death protein 1) monoclonal antibody, was shown to be a safe and effective therapy for kidney cancer even in patients who continued treatment after their disease progressed. Results ...

Kidney Cancer

Lenvatinib in Combination With Everolimus in Advanced Renal Cell Carcinoma

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On May 13, 2016, lenvatinib (Lenvima) was approved for use in...

kidney cancer

David F. McDermott, MD, and Toni K. Choueiri, MD, on Advanced RCC: Nivolumab in Previously Treated Patients

David F. McDermott, MD, of Beth Israel Deaconess Medical Center, and Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discuss an update on data from phase I and II studies of nivolumab given to patients with metastatic renal cell carcinoma, including long-term overall survival and potential predictors of benefit (Abstract 4507).

Kidney Cancer

FDA Approves Lenvatinib in Combination With Everolimus in Advanced Renal Cell Carcinoma

On May 13, 2016, the U.S. Food and Drug Administration (FDA) approved lenvatinib capsules (Lenvima) in combination with everolimus (Afinitor) for the treatment of advanced renal cell carcinoma following one prior antiangiogenic therapy. Lenvatinib was first approved in 2015 for the treatment of...

Kidney Cancer

Curb Your Enthusiasm: No Benefit of Adjuvant Sorafenib or Sunitinib in Nonmetastatic Renal Cell Carcinoma

Renal cell carcinoma is the most common cancer of the kidneys. Up to 30% of patients present with advanced/metastatic disease, and recurrence can develop in patients at high risk treated by nephrectomy for localized tumors. Renal cell carcinoma is notoriously resistant to chemotherapy and...

Kidney Cancer

No Disease-Free Survival Benefit of Adjuvant Sunitinib or Sorafenib in High-Risk Nonmetastatic Renal Cell Carcinoma

In the phase III ECOG-ACRIN E2805 trial reported in The Lancet by Naomi B. Haas, MD, of Abramson Cancer Center, University of Pennsylvania, and colleagues, no benefit of adjuvant vascular endothelial growth factor receptor (VEGFR) inhibitor treatment with sunitinib or sorafenib (Nexavar) was...

Kidney Cancer

Crizotinib Active in Orphan Kidney Malignancy

Crizotinib (Xalkori) achieved overall and durable responses in advanced inoperable papillary renal cell carcinoma type 1 characterized by somatic MET mutations, according to an investigator-initiated trial conducted by the European Organization for Research and Treatment of Cancer (EORTC).1 “To...

Kidney Cancer

Cabozantinib in Advanced Renal Cell Carcinoma

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On April 25, 2016, a tablet formulation of cabozantinib...

kidney cancer

FDA Approves Lenvatinib in Combination With Everolimus in Advanced Renal Cell Carcinoma

On May 13, 2016, the U.S. Food and Drug Administration (FDA) approved lenvatinib capsules (Lenvima), in combination with everolimus (Afinitor) for the treatment of advanced renal cell carcinoma following one prior antiangiogenic therapy. Lenvatinib was first approved in 2015 for the treatment...

Kidney Cancer

FDA Approves Cabozantinib in Patients With Renal Cell Carcinoma Who Have Received Prior Antiangiogenic Therapy

On April 25, 2016, the U.S. Food and Drug Administration (FDA) approved cabozantinib ­(Cabometyx) tablets for the treatment of advanced renal cell carcinoma in patients who have received prior antiangiogenic therapy. Cabozantinib is a dual tyrosine kinase inhibitor of MET and VEGFR2. The capsule...

kidney cancer

FDA Approves Cabozantinib in Patients With Renal Cell Carcinoma Who Have Received Prior Antiangiogenic Therapy

On April 25, 2016, the U.S. Food and Drug Administration (FDA) approved cabozantinib (Cabometyx) tablets for the treatment of advanced renal cell carcinoma in patients who have received prior antiangiogenic therapy. Cabozantinib is a dual tyrosine kinase inhibitor of MET and VEGFR2. The...

solid tumors
kidney cancer

Study Finds Apitolisib Less Effective Than Everolimus in Metastatic Renal Cell Carcinoma

As reported in the Journal of Clinical Oncology by Powles et al, the dual PI3K/mTOR inhibitor apitolisib was inferior to the mTOR inhibitor everolimus (Afinitor) in progression-free survival in a phase II trial in patients with metastatic clear cell renal cell carcinoma progressing on or after...

kidney cancer

No Disease-Free Survival Benefit of Adjuvant Sunitinib or Sorafenib in High-Risk Nonmetastatic Renal Cell Carcinoma

In a phase III trial (ECOG-ACRIN E2805) reported in The Lancet by Haas et al, no benefit of adjuvant VEGFR (vascular endothelial growth factor receptor) inhibitor treatment with sunitinib or sorafenib (Nexavar) was observed vs placebo in patients with completely resected high-risk nonmetastatic...

Kidney Cancer

Genomic, Molecular Differences in Tumor Biology May Explain Inferior Survival in African Americans With Kidney Cancer

African Americans who develop metastatic renal cell carcinoma have had worse survival historically than whites. With the advent of targeted therapy, the hope is that the gap in survival would be narrowed. However, a new study has shown that survival for African Americans with metastatic renal cell...

kidney cancer
kidney cancer

Removal of Complex Renal Tumors Performed Safely by Robotic Surgery in Selected Patients

Renal cell carcinoma can sometimes spread to the inferior vena cava, posing a threat to the heart and brain. Robotic nephrectomy for inferior vena cava tumor thrombus has favorable outcomes in selected patients compared with open surgery, which can have a high rate of complications, reported Abaza...

kidney cancer

Two Contenders for Second-Line Treatment of Advanced Renal Cell Carcinoma

Options for second-line therapy of advanced/metastatic renal cell carcinoma are expanding. Updates from the CheckMate 025 and METEOR ­trials presented at the 2016 Genitourinary Cancers Symposium solidify the value of both nivolumab (Opdivo, an immune checkpoint inhibitor) and cabozantinib...

kidney cancer

Eric Jonasch, MD, on Kidney Cancer: Current and Novel Treatment Options

Eric Jonasch, MD, of The University of Texas, MD Anderson Cancer Center, discusses the progress being made in kidney cancer treatment and the clinical trials that focused on sunitinib, sorafenib, and everolimus, among others.

kidney cancer

Cora N. Sternberg, MD, on New Targets in Renal Cell Carcinoma

Cora N. Sternberg, MD, of San Camillo Forlanini Hospital, summarizes a teaching lecture on new targets in renal cell carcinoma, and discusses what to expect for the future of treating RCC.

kidney cancer

Brian I. Rini, MD, on A Cancer Vaccine for Renal Cell Carcinoma

Brian I. Rini, MD, of the Cleveland Clinic Taussig Cancer Institute, discusses the results from a phase III study investigating a multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic renal cell carcinoma (Abstract 17LBA).

kidney cancer

Robert J. Motzer, MD, on Phase III Results of CheckMate 025 Nivolumab vs Everolimus in Advanced RCC

Robert J. Motzer, MD, of Memorial Sloan Kettering Cancer Center, discusses the results of this study, which could well change the treatment paradigm in patients with previously treated metastatic renal cell carcinoma (Abstract 3LBA).

kidney cancer

Toni K. Choueiri, MD, on Cabozantinib vs Everolimus in Patients With Advanced Renal Cell Carcinoma

Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discusses results of the phase III METEOR trial in advanced renal cell carcinoma, which evaluated the efficacy of cabozantinib compared to everolimus in patients with disease progression after VEGFR-targeted therapy (Abstract 4LBA).

kidney cancer

Toni Choueiri, MD: Renal Cancer Update

Toni Choueiri, MD, of the Dana-Farber Cancer Institute, summarizes key points from a session he chaired on clear and non-clear cell renal cancer, including information on molecular genetics and its impact on treatment, how to treat patients with non-clear cell histology, and the best strategy for treating clear cell cancer.

kidney cancer

Hans-Joerg Hammers, MD, PhD, on Renal Cancer: Using Immune Checkpoint Blockers in the Clinic

Hans-Joerg Hammers, MD, PhD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, summarizes this keynote lecture on kidney cancer, which included discussion of the current role of PD-1 monotherapy and future PD-1 combination therapies for renal cell carcinoma.

kidney cancer

Bernard J. Escudier, MD, on Renal Cell Carcinoma: Results From the METEOR Trial (French Language Version)

Bernard J. Escudier, MD, of the Institut Gustave Roussy, discusses in French a subgroup analyses of this phase III study of cabozantinib vs everolimus in patients with advanced renal cell carcinoma (Abstract 499).

kidney cancer

Bernard J. Escudier, MD, on Renal Cell Carcinoma: Results From the METEOR Trial

Bernard J. Escudier, MD, of the Institut Gustave Roussy, discusses a subgroup analyses of this phase III study of cabozantinib vs everolimus in patients with advanced renal cell carcinoma (Abstract 499). To see the French language version of this video, click here.

Kidney Cancer

Sunitinib-induced Hypertension May Be Efficacy Biomarker in Patients with Metastatic Renal Cell Carcinoma

A retrospective exploratory analysis of pooled efficacy data from more than 500 patients with metastatic renal cell carcinoma treated with sunitinib (Sutent) “support the hypothesis that hypertension may be a viable biomarker of antitumor efficacy in this patient population,” according to a report...

Kidney Cancer

Studies Explore Potential Benefits of Sunitinib before Nephrectomy in Metastatic Clear Cell Renal Cancer

The multitargeted tyrosine kinase inhibitor sunitinib (Sutent) is established as first-line therapy in metastatic clear cell renal cancer. Data supporting use of cytoreductive nephrectomy in metastatic clear cell renal cancer come from the pre–targeted therapy era, when less-effective immune...

Kidney Cancer

Axitinib Improves Progression-free Survival over Sorafenib in Advanced Renal Cell Carcinoma

A randomized comparative effectiveness phase III trial demonstrated significantly superior efficacy for the tyrosine kinase inhibitor axitinib compared to sorafenib (Nexavar) in patients with advanced renal cell carcinoma (RCC). These data suggest that axitinib may become a new standard of care for ...

Kidney Cancer

Adjuvant Immunotherapy Provides No Clinical Benefit in Patients with High‑risk Renal Cell Carcinoma

For renal cell carcinoma patients at high risk of relapse following nephrectomy, adjuvant therapy with the combination of interleukin-2 (Proleukin), interferon alfa, and fluorouracil (5-FU) provides no survival benefit over observation alone, according to a phase III trial conducted by the European ...

Kidney Cancer
Prostate Cancer

Novel Management Strategies Assessed in Renal Cell and Prostate Cancers

At the Best of ASCO Miami meeting, William Oh, MD, of the Tisch Cancer Institute, Mount Sinai School of Medicine, New York, described new trends and remaining questions in the management of renal cell and prostate cancers. Axitinib vs Sorafenib in Second-line RCC Axitinib, a potent and selective...

Kidney Cancer

Significantly Longer Survival with Axitinib Compared to Sorafenib in Patients with Renal Cell Carcinoma

A phase III study comparing the vascular endothelial growth factor receptor (VEGFR) inhibitors axitinib and sorafenib (Nexavar) as second-line therapy in patients with metastatic renal cell carcinoma found that axitinib produced significantly longer progression-free survival. Published in The...

Kidney Cancer

ODAC Backs Axitinib for Kidney Cancer

The FDA’s Oncologic Drugs Advisory Committee voted 13-0 that Pfizer’s drug axitinib (Inlyta) had a favorable benefit-risk profile for patients with advanced renal cell carcinoma after initial treatment has failed. The FDA is due to make a final decision in the first half of 2012. Panelists said the ...

Kidney Cancer

Tyrosine Kinase Inhibitor Therapy Yields Complete Remission in Patients with Metastatic Renal Cell Carcinoma

Targeted therapies have markedly improved outcomes in patients with advanced renal cell carcinoma, with median overall survival of greater than 2 years having been observed with sunitinib (Sutent) treatment. Objective responses, consisting mostly of partial responses, are observed in approximately...

Kidney Cancer

Axitinib Receives FDA Approval in Advanced Renal Cell Carcinoma

The FDA has approved the kinase inhibitor axitinib (Inlyta) for the treatment of advanced renal cell carcinoma after failure of one prior systemic therapy. The approval is based on an international, randomized, open-label trial that enrolled 723 patients: 361 were assigned to receive axitinib at 5 ...

Kidney Cancer

What You Need to Know About Axitinib, New Agent for Treating Advanced Renal Cell Carcinoma

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication In January 2012, the second-generation vascular...

Prostate Cancer
Bladder Cancer
Kidney Cancer

Important News Briefs: New Data Reported in Prostate, Bladder, and Kidney Cancers

The recent 2012 Genitourinary Cancers Symposium featured a wealth of presentations on prostate, bladder, kidney, and other genitourinary cancers. Brief summaries of some of the oral and poster sessions are presented. Exercise and Recurrence Vigorous exercise has been shown to reduce cancer...

Advertisement

Advertisement

Advertisement